CRISPR Therapeutics CRSP Other Working Capital
Other Working Capital at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's other working capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's other working capital?
- CRISPR Therapeutics (CRSP) reported other working capital of -$8.8M in Q1 2026.
- How has CRISPR Therapeutics's other working capital changed year-over-year?
- CRISPR Therapeutics's other working capital decreased by 290.6% year-over-year, from -$2.25M to -$8.8M.
- What is the long-term trend for CRISPR Therapeutics's other working capital?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's other working capital has grown at a 13.6% compound annual growth rate (CAGR), from -$14.11M to $23.53M.
- What does other working capital mean?
- Net change in working capital items not separately classified — a residual balancing item.